PeptideLabs Logo
PeptideLabs
Documentación de Calidad
Back to all 64 profiles
No uniform peptide protocolNo aprobado por FDA/EMA

Community protocol · 5-Amino-1MQ

5-Amino-1MQ: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: 5-amino-1-methylquinolinium · NNMT inhibitor

Sources checked: 27 August 2026

Aviso importante de seguridad y responsabilidad

Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

5-Amino-1MQ

No es un péptido. Se estudia de forma preclínica en metabolismo energético y adiposo; faltan datos humanos sólidos.

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Amounts, timing and cycles

No uniform peptide protocol

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitución y conversión U-100

No generic calculator

Reconstitution is not generally applicable to this substance or product class. Form, concentration and handling must come from the exact authentic product and its official labelling.

Reconstitution is not generally applicable to this substance or product class. Form, concentration and handling must come from the exact authentic product and its official labelling.

Mechanism and research questions

Experimental small-molecule inhibitor of nicotinamide N-methyltransferase

5-Amino-1MQ is classified as “Experimental small-molecule inhibitor of nicotinamide N-methyltransferase”. No es un péptido. Se estudia de forma preclínica en metabolismo energético y adiposo; faltan datos humanos sólidos. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Inhibición de NNMT

Esto estudia cómo la inhibición de una enzima metabólica llamada NNMT podría afectar el gasto energético de las células grasas, de forma similar a quitar un tope de freno. Se miden la actividad enzimática y los marcadores metabólicos en modelos celulares.

02

Metabolismo de los adipocitos

Esto estudia cómo las células grasas almacenan, liberan y queman energía, de forma similar a observar cómo se llena y vacía un tanque de almacenamiento. Los investigadores suelen medir el tamaño de las células grasas, la actividad enzimática y el gasto energético en modelos celulares o animales.

03

Metabolismo energético celular

Los investigadores estudian cómo las células producen y utilizan energía, en particular a través de las mitocondrias, de forma similar a medir la eficiencia con la que un motor quema combustible. Las medidas habituales incluyen el consumo de oxígeno y la producción de energía en modelos celulares.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Foros de control de peso

En estos foros, los usuarios comparan sus propias trayectorias de peso, efectos secundarios y cambios percibidos en el apetito entre diferentes productos. A menudo se comparten fotos de antes y después y cronogramas personales. Estos relatos y afirmaciones de marketing de proveedores no son prueba científica de eficacia.

Foros de biohacking y longevidad

Los usuarios comparan combinaciones de péptidos ensambladas por ellos mismos con el objetivo de influir en los procesos de envejecimiento o los niveles de energía, a menudo basándose en análisis de sangre o escalas subjetivas de bienestar. Los autoexperimentos personales y las promesas de marketing no reemplazan a los estudios controlados a largo plazo en humanos.

Discusión de origen y pureza

Se discute qué proveedores se consideran más confiables y cómo difieren los resultados de las pruebas de pureza entre lotes. Estas evaluaciones comunitarias se basan en muestras limitadas y no reemplazan las pruebas de laboratorio independientes de cada lote individual.

Adverse effects and risk boundaries

  • Según la diana pueden aparecer efectos gastrointestinales, deshidratación y cambios en glucosa o apetito; los fármacos incretínicos también pueden incluir advertencias biliares, pancreáticas y de retinopatía.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • El embarazo, los trastornos graves del vaciamiento gástrico y las enfermedades pancreáticas, biliares, renales o endocrinas requieren evaluación profesional; la ficha concreta puede añadir contraindicaciones.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Según la sustancia e indicación se revisan peso, presión arterial, hidratación, glucosa/HbA1c, función renal y hepática y medicación concomitante; los síntomas guían otras pruebas.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclínico

No se ha demostrado una eficacia y seguridad sólidas en humanos.

Published evidence

Los datos disponibles provienen principalmente de modelos animales o celulares; faltan datos sólidos de eficacia y seguridad en humanos.

5-Amino-1MQ no es un péptido, sino un inhibidor de molécula pequeña de la NNMT, a diferencia de candidatos metabólicos basados en péptidos.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

No aprobado por FDA/EMA

No existe medicamento aprobado por FDA o EMA; eficacia y seguridad no están establecidas.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.